Yingsheng Biology, a Chinese biotechnology firm that provides mass spectrometry (MS) services, announced on Wednesday that it has raised nearly RMB100 million (US$14.47 million) in a series C round of financing. Investors of the new round include Chinese venture capital firm BioVenture and state-owned enterprise group Xiamen C&D Corporation Limited, according to a company statement […]

Chinese Biotech Firm Yingsheng Biology Gets $14M In Series C Round comes originally from China Money Network. All Rights Reserved.